Top Story Today
42,000 Americans Had Zero Approved Treatments. J&J Just Changed That.
For decades, patients with warm autoimmune hemolytic anemia (a condition where your immune system destroys your own red blood cells) had exactly zero FDA-approved therapies. J&J has submitted IMAAVY (nipocalimab) for approval, seeking to make it the first, working by blocking a receptor called FcRn that normally recycles the harmful antibodies causing the damage. The response rate was modest at 23.7% versus 7.7% on placebo, but when the alternative is literally nothing, modest is transformative. J&J paid $6.5 billion for the drug's developer in 2020 and is now chasing approvals across a half-dozen other antibody-driven diseases.
Why it matters: This filing positions FcRn blockade as a viable mechanism across antibody-mediated diseases and could give J&J first-mover status in a brand-new rare disease market, with implications for the broader FcRn inhibitor arms race against Argenx, UCB, and others.
Read more →Diagnostics and Devices
A Blood Test That Could Replace the $5,000 Alzheimer's Brain Scan
Roche just got FDA clearance for a blood test that detects Alzheimer's-related amyloid plaques with roughly 90% accuracy. The Elecsys pTau217 test runs on over 4,500 machines already installed in U.S. labs, and research suggests it could eliminate 80-85% of the need for expensive PET scans and invasive spinal taps. With anti-amyloid drugs now available but diagnostic bottlenecks blocking patient access, this could be the infrastructure shift Alzheimer's care has been waiting for.
Read more →The FDA Just Cleared a Robot to Draw Your Blood
Vitestro's Aletta is the first standalone robotic blood-draw device authorized in the U.S., scoring a 94.5% first-stick success rate that jumps to 92.7% on difficult veins (where humans often drop to 75-80%). The FDA had to create an entirely new device category to approve it, building a regulatory pathway for every autonomous medical robot that follows.
Read more →Global Approvals
The First Drug That Could Actually Cure Hepatitis B
Japan just approved GSK's Hibsago (bepirovirsen), the world's first therapy designed to functionally cure chronic hepatitis B rather than just suppress it indefinitely. In trials, 19% of patients achieved lasting viral clearance after stopping treatment; the placebo rate was zero. With 240 million people infected globally and fewer than 5% receiving therapy, GSK is projecting over 2 billion pounds in peak annual sales. U.S. priority review is underway, with an FDA decision expected in October.
Read more →The First Drug That Fixes Narcolepsy's Root Cause
Takeda's oveporexton earned Japanese approval as the first medicine to restore orexin signaling in narcolepsy type 1, targeting the disease's actual cause instead of masking symptoms with stimulants. The drug hit every endpoint in two pivotal trials, and its success validates an entire class of brain-chemistry therapies with potential beyond narcolepsy.
Read more →Industry Trends
Boston Biotech Is Getting Richer and Thinner at the Same Time
Massachusetts biotech companies pulled in $3.45 billion in venture capital during the first half of 2026 (up 25% year over year), but the state's biopharma workforce shrank, dropping about 1,100 R&D jobs. Average Series A rounds ballooned to roughly $76.7 million while seed rounds averaged about $8.1 million. The message: more money is chasing fewer, leaner companies.
Read more →Lady Gaga Co-Founded a Biotech Startup. It's Weirder Than You Think.
Lady Gaga and fiance Michael Polansky quietly built Outer Biosciences, a $23 million startup that keeps living human skin functional in a lab for weeks and uses AI to discover skincare ingredients. The platform is real (there's a preprint), the team has legitimate life sciences experience, and it's already running projects with Gaga's beauty brand Haus Labs.
Read more →